Moreau, Mathilde, Alouani, Emily, Flecchia, Clémence, Falcoz, Antoine, Gallois, Claire, Auclin, Edouard, André, Thierry, Cohen, Romain, Hollebecque, Antoine, Turpin, Anthony, Pernot, Simon, Masson, Thérèse, Di Fiore, Frederic, Dutherge, Marie, Mazard, Thibault, Hautefeuille, Vincent, Van Laethem, Jean-Luc, De la Fouchardière, Christelle, Perkins, Géraldine, and Ben-Abdelghani, Meher
One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient DNA mismatch repair system/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer. However, few studies have compared ICI with CT in other advanced dMMR/MSI-H digestive tumors. In this multicenter study, we included patients with advanced dMMR/MSI-H non-colorectal digestive tumors treated with chemotherapy and/or ICIs. Patients were divided retrospectively into two groups, a CT group and an immunotherapy (IO) group. The primary endpoint was progression-free survival (PFS). A propensity score approach using the inverse probability of treatment weighting (IPTW) method was applied to deal with potential differences between the two groups. 133 patients (45.1/27.1/27.8% with gastric/small bowel/other carcinomas) were included. The majority of patients received ICI in 1st (29.1%) or 2nd line (44.4%). The 24-month PFS rates were 7.9% in the CT group and 71.2% in the IO group. Using the IPTW method, IO treatment was associated with better PFS (HR=0.227; 95% CI 0.147–0.351; p < 0.0001). The overall response rate was 26.3% in the CT group versus 60.7% in the IO group (p < 0.001) with prolonged duration of disease control in the IO group (p < 0.001). In multivariable analysis, predictive factors of PFS for patients treated with IO were good performance status, absence of liver metastasis and prior primary tumor resection, whereas no association was found for the site of the primary tumor. In the absence of randomized trials, our study highlights the superior efficacy of ICI compared with standard-of-care therapy in patients with unresectable or metastatic dMMR/MSI-H non-colorectal digestive cancer, regardless of tumor type, with acceptable toxicity. • Immunotherapy (IO) has high efficacy in mismatch-repair deficient (dMMR) tumors. • No trial compared chemotherapy (CT) and ICI in non-colorectal dMMR digestive tumors. • ICI has higher progression-free survival, regardless primary tumor site. [ABSTRACT FROM AUTHOR]